EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting MDM2-p53 interaction for breast cancer therapy

Amjad Yousuf, Najeeb Ullah Khan

Oncology Research · 2025

DOI: 10.32604/or.2025.058956 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Amjad Yousuf und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Madinah, 41477, Saudi Arabia. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Breast Neoplasms, Tumor Suppressor Protein p53, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is a significant global concern, with limited effective treatment options. Therefore, therapies with high efficacy and low complications, unlike the existing chemotherapies, are urgently required. To address this issue, advances have been made in therapies targeting molecular pathways related to the murine double minute 2 proto-oncogene (MDM2)-tumor proteinp53 (TP53) interaction. This review aims to investigate the efficacy of MDM2 inhibition in restoring TP53 activity in breast cancer cells, as evidenced by clinical studies, reviews, and trials. TP53 is a tumor suppressor and MDM2 facilitates proteasomal degradation of TP53. MDM2 and TP53 activity is tightly regulated. However, cancerous breast cells overexpress MDM2 through five hypothesized mechanisms. Consequently, TP53 levels decrease with increased tumor cell proliferation. Three strategies have been identified for controlling MDM2 upregulation in cells with wild-type or mutated TP53. MDM2 inhibitors (MDM2i) are administered in combination with existing chemotherapies to reduce their effects on healthy cells. Few clinical and preclinical studies have been conducted using MDM2i, which necessitates high-quality clinical trials to support their therapeutic potential in breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Breast NeoplasmsTumor Suppressor Protein p53Antineoplastic AgentsHumansFemaleProto-Oncogene MasMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

Breast cancerMurine double minute 2 proto-oncogene (MDM2)Targeted therapyTumor protein 53(TP53)

Substanzen

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Proto-Oncogene MasMAS1 protein, humanMDM2 protein, humanTP53 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Madinah, 41477, Saudi Arabia.
  • Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Peshawar, 25130, Pakistan.

Zitieren

APA

Yousuf, A., & Khan, N. U. (2025). Targeting MDM2-p53 interaction for breast cancer therapy. Oncology Research. https://doi.org/10.32604/or.2025.058956

Vancouver

Yousuf A, Khan NU. Targeting MDM2-p53 interaction for breast cancer therapy. Oncology Research. 2025. doi:10.32604/or.2025.058956

BibTeX
@article{Yousuf2025,
  author = {Yousuf, Amjad and Khan, Najeeb Ullah},
  title = {Targeting MDM2-p53 interaction for breast cancer therapy},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.058956}
}
Kostenlos starten →